Latest ASX Announcements

Video: NDF Research interview on Phase 2a results

In the interview, Kathy Harrison and Associate Professor David Packham, a Principal Investigator in the DMX-200 Phase 2a study and Director of Melbourne Renal Research Group, discusses Dimerix’s Phase 2a trial result of DMX-200 with Stuart Roberts, Senior Analyst with NDF Research.

The full interview is available here.

By | 2017-07-17T08:22:20+00:00 July 14th, 2017|Latest ASX Announcements, Media and Analyst Coverage|

Dimerix Reports Positive Results from Phase 2a Trial of DMX-200 in Chronic Kidney Disease

DMX-200 Phase 2a clinical trial meets primary safety endpoint and demonstrates encouraging efficacy in a clinically meaningful number of patients 

  •  25% of patients achieved a greater than 50% reduction in proteinuria, beyond that achieved with the highest dosage of current standard of care therapy
  •  45% of […]
By | 2017-07-12T07:54:11+00:00 July 12th, 2017|Latest ASX Announcements|

ASX Announcement – CEO Kathy Harrison on Proactive Investors Stocktube

Dimerix today published a recorded interview with Chief Executive Officer Kathy Harrison.

The recent interview highlighted a number of important points including:

− the innovative clinical and commercial development pathway for Dimerix’s lead compound (DMX-200) as a potential new therapy for treating chronic kidney disease

− the global market size and significant unmet medical need for new kidney […]

By | 2017-06-15T09:13:17+00:00 June 14th, 2017|Latest ASX Announcements|